For many patients struggling with chronic rhinitis, medical management does not provide the long-lasting relief they seek, and they remain tied to tissues and sprays to cope with their daily symptoms.
Most current, in-office rhinitis treatments are not comprehensive solutions, and surgical options like septoplasty, turbinate reduction, or other ablative technologies have mixed patient responses and may not alleviate all symptoms.
Compact and portable, the Aerin® Console and the RhinAer Stylus fit seamlessly into any clinic, office, or hospital environment. RhinAer is a convenient and efficient treatment option to integrate into your practice.
RhinAer treats the root causes of rhinorrhea / post-nasal drip and congestion in a single session.
The RhinAer stylus employs proprietary, temperature-controlled radiofrequency (RF) technology optimized for the nasal airway. Once the stylus is activated, the Aerin System automatically maintains the tip’s target temperature for therapeutic benefit while sparing surrounding tissue, including mucosa.
Patients undergoing the treatment experience minimal discomfort and recovery time.* In a recent study with the Aerin Console, there was no aerosol generation above background levels, thereby enhancing safety for physicians and staff.1
1-Year results from the RhinAer pivotal trial2
80.9% of patients experienced a significant (p<0.001) and sustained reduction in their chronic rhinitis symptoms through 52 weeks
57.6% overall rTNSS reduction with all rTNSS sub-scores (rhinorrhea, nasal congestion, nasal itching, and sneezing) measured statistically significant improvements (p<0.001) over baseline at 52 weeks
Mean post-nasal drip and chronic cough scores at baseline and follow-up. Bars represent 95% confidence intervals. All values were statistically significantly improved from baseline throughout follow‑up (p < .001 at all time points based on linear mixed-effect model).
Post-nasal drip and chronic cough symptom scores remained significantly improved from baseline at all follow-up time points (p<0.001)
Treatment resulted in statistically significant mean rTNSS improvements for patients suffering from chronic rhinitis of allergic, non-allergic, and unknown etiologies (p<0.001)
0 serious adverse events related to the device and/or procedure were observed
0 device- or procedure-related headaches were reported through 52 weeks
Study design: Prospective, multi-center, non-randomized study was conducted to evaluate the safety and efficacy of the RhinAer® Stylus (RhinAer) on patients with chronic rhinitis symptoms for at least 6 months duration.
Patients: A total of 50 subjects were treated with RhinAer across 5 US centers and followed-up at 2, 4, 12, 26, and 52 weeks post-procedure.
Primary endpoint:
Janet
RhinAer Patient
“I feel like I can live again and do things I like to do. I’m not sneezing. I’m not blowing my nose. It’s just amazing."
* Individual results may vary
References:
The RhinAer Stylus plugs into the compact and portable Aerin® Console. The console may also be used with the VivAer® Stylus to treat the entire nasal valve and provide lasting relief for patients suffering from nasal airway obstruction.
VivAer.com